Literature DB >> 9552353

Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.

G J Wiederrecht1, C J Sabers, G J Brunn, M M Martin, F J Dumont, R T Abraham.   

Abstract

The immunosuppressant drug, rapamycin (RAP), is a potent inhibitor of IL-2-dependent T-cell proliferation. The antiproliferative effect of RAP is mediated through the formation of an active complex with its cytosolic receptor protein, FKBP12. The molecular target of the FKBP12.RAP complex is a putative lipid kinase termed the mammalian Target Of Rapamycin (mTOR). This review will discuss recent findings suggesting that mTOR is a novel regulator of G1- to S-phase progression in eukaryotic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9552353     DOI: 10.1007/978-1-4615-1809-9_5

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN: 1087-2957


  38 in total

1.  mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells.

Authors:  Charles A Easley; Ahmi Ben-Yehudah; Carrie J Redinger; Stacie L Oliver; Sandra T Varum; Vonya M Eisinger; Diane L Carlisle; Peter J Donovan; Gerald P Schatten
Journal:  Cell Reprogram       Date:  2010-06       Impact factor: 1.987

2.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.

Authors:  Greg M Delgoffe; Thomas P Kole; Yan Zheng; Paul E Zarek; Krystal L Matthews; Bo Xiao; Paul F Worley; Sara C Kozma; Jonathan D Powell
Journal:  Immunity       Date:  2009-06-19       Impact factor: 31.745

3.  Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation.

Authors:  M W Laschke; A Elitzsch; C Scheuer; J H Holstein; B Vollmar; M D Menger
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

4.  Should diabetic women with breast cancer have their own intervention studies?

Authors:  David A Potter; Douglas Yee; Zhijun Guo; Mariangellys Rodriguez
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

5.  Kaempferol attenuates imiquimod-induced psoriatic skin inflammation in a mouse model.

Authors:  C Liu; H Liu; C Lu; J Deng; Y Yan; H Chen; Y Wang; C-L Liang; J Wei; L Han; Z Dai
Journal:  Clin Exp Immunol       Date:  2019-08-26       Impact factor: 4.330

6.  Target therapy in gastrointestinal tract sarcoma: What is new?

Authors:  Bruno Vincenzi; Anna Maria Frezza; Daniele Santini; Giuseppe Tonini
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

Review 7.  The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Authors:  Sushma Vemulapalli; Alain Mita; Yesid Alvarado; Kamalesh Sankhala; Monica Mita
Journal:  Target Oncol       Date:  2011-04-28       Impact factor: 4.493

8.  Rapamycin affects early fracture healing in mice.

Authors:  J H Holstein; M Klein; P Garcia; T Histing; U Culemann; A Pizanis; M W Laschke; C Scheuer; C Meier; H Schorr; T Pohlemann; M D Menger
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

Review 9.  Mammalian target of rapamycin (mTOR) Inhibitors.

Authors:  Janice P Dutcher
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 10.  Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.

Authors:  Justin Cidado; Ben Ho Park
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-08-04       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.